MEI Pharma Inc. (Nasdaq: MEIP), a San Diego-based oncology company focused on the clinical development of novel therapies for cancer, announced the appointment of David Urso as senior vice president of corporate development and general counsel.
Urso joins MEI Pharma with more than two decades of experience in the life science industry, most recently as COO and general counsel at Tioga Pharmaceuticals, a company he co-founded in 2005 as a principal at Forward Ventures.
"David brings a wealth of experience to the company, from corporate development and operations to legal affairs," said Daniel P. Gold, Ph.D., president and CEO of MEI Pharma. "He comes equipped with a scientific background in molecular immunology, legal expertise in corporate securities and intellectual property and a track record of licensing and strategic alliance transactions. His comprehensive life science perspective will serve us well as we continue to build an oncology drug development company."
While co-founding Tioga, Urso was a principal at Forward Ventures, where he was responsible for identifying and developing life science venture capital investments. Prior to joining Forward Ventures in 2002, he was director of corporate development and legal affairs at DNA Sciences Inc. Previously, he worked as an attorney in the corporate securities and licensing groups at Wilson Sonsini Goodrich & Rosati LLP and Cooley Godward LLP, after beginning his career as a bench scientist at SmithKline Beecham and the University of Pennsylvania Medical School.
Urso received a J.D. from Harvard Law School and a B.A. in molecular biology and philosophy from Reed College.